Best in Business Awards - 2024

OVERVIEW: ivWatch is setting a new standard for IV therapy with its FDA-cleared Class II medical device for continuous IV monitoring. By leveraging advanced optical technology, ivWatch detects changes in tissue properties around an IV site, offering early detection of infiltration or extravasation, a common complication affecting 50% of peripheral IVs annually. This innovative solution reduces patient injury risks and enhances vascular injury diagnosis accuracy.

IMPACT ACHIEVED: In trials, ivWatch technology achieved a 100% reduction in extravasation injuries while monitoring over 300,000 patients for 9 million hours to date. Notable milestones include a recent FDA clearance to monitor iron sucrose infusions, which carry a high risk of lifelong tissue damage. Single-use sensor sales surged 83% from 2023 to 2024, reflecting rapid adoption. The company also expanded into 13 countries and achieved a 430% increase in product evaluations over the past year.

DISTINCTIVE EDGE: What sets ivWatch apart is its unparalleled precision—performing 18,000 checks per hour—and its proven track record with top institutions, including three of the top 10 U.S. children’s hospitals. With 69 patents, ivWatch is redefining IV therapy as a safer, more reliable standard of care, with a global footprint poised for continued growth.